

FORM NO. MGT-7

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]



Annual Return (other than OPCs and Small Companies)

Form language English Hindi

Refer the instruction kit for filing the form.

I. REGISTRATION AND OTHER DETAILS

(i) * Corporate Identification Number (CIN) of the company

U74999TG2000PTC035826

Pre-fill

Global Location Number (GLN) of the company

* Permanent Account Number (PAN) of the company

AABCG3208J

(ii) (a) Name of the company

ARAGEN LIFE SCIENCES PRIVATE

(b) Registered office address

Plot 28A,
IDA Nacharam,
Hyderabad
Telangana
500076

(c) *e-mail ID of the company

compliances@aragen.com

(d) *Telephone number with STD code

04066929989

(e) Website

(iii) Date of Incorporation

07/12/2000

(iv)	Type of the Company	Category of the Company	Sub-category of the Company
	Private Company	Company limited by shares	Indian Non-Government company

(v) Whether company is having share capital

Yes No

(vi) *Whether shares listed on recognized Stock Exchange(s)

Yes No

(vii) *Financial year From date (DD/MM/YYYY) To date (DD/MM/YYYY)

(viii) *Whether Annual general meeting (AGM) held Yes No

(a) If yes, date of AGM

(b) Due date of AGM

(c) Whether any extension for AGM granted Yes No

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

*Number of business activities

S.No	Main Activity group code	Description of Main Activity group	Business Activity Code	Description of Business Activity	% of turnover of the company
1	M	Professional, Scientific and Technical	M5	Scientific research and development	69.57
2	C	Manufacturing	C6	Chemical and chemical products, pharmaceuticals, medicinal chemical and	30.43

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

*No. of Companies for which information is to be given

Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/ Joint Venture	% of shares held
1	GVK DAVIX TECHNOLOGIES PR	U74110TG2005PTC045481	Holding	49.75
2	ARAGEN BIOSCIENCE INC		Subsidiary	100
3	ARAGEN LIFE SCIENCES B.V.		Subsidiary	100
4	INTOX PRIVATE LIMITED	U74999PN2000PTC015116	Subsidiary	56.82
5	ARAGEN FOUNDATION	U85300DL2021NPL391515	Subsidiary	100

IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

(i) *SHARE CAPITAL**(a) Equity share capital**

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Total number of equity shares	115,000,000	68,138,063	68,138,063	68,138,063
Total amount of equity shares (in Rupees)	1,150,000,000	681,380,630	681,380,630	681,380,630

Number of classes

1

Class of Shares	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Equity				
Number of equity shares	115,000,000	68,138,063	68,138,063	68,138,063
Nominal value per share (in rupees)	10	10	10	10
Total amount of equity shares (in rupees)	1,150,000,000	681,380,630	681,380,630	681,380,630

(b) Preference share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid-up capital
Total number of preference shares	0	0	0	0
Total amount of preference shares (in rupees)	0	0	0	0

Number of classes

0

Class of shares	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Number of preference shares				
Nominal value per share (in rupees)				
Total amount of preference shares (in rupees)				

(c) Unclassified share capital

Particulars	Authorised Capital
Total amount of unclassified shares	0

(d) Break-up of paid-up share capital

Class of shares	Number of shares			Total nominal amount	Total Paid-up amount	Total premium
	Physical	DEMAT	Total			
Equity shares						
At the beginning of the year	802,452	66,180,000	66982452	669,824,520	669,824,520	

Increase during the year	48,835	1,106,776	1155611	11,556,110	11,556,110	0
i. Public Issues	0	0	0	0	0	0
ii. Rights issue	0	0	0	0	0	0
iii. Bonus issue	0	0	0	0	0	0
iv. Private Placement/ Preferential allotment	0	0	0	0	0	0
v. ESOPs	48,835	1,106,776	1155611	11,556,110	11,556,110	0
vi. Sweat equity shares allotted	0	0	0	0	0	0
vii. Conversion of Preference share	0	0	0	0	0	0
viii. Conversion of Debentures	0	0	0	0	0	0
ix. GDRs/ADRs	0	0	0	0	0	0
x. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Buy-back of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify						
At the end of the year	851,287	67,286,776	68138063	681,380,630	681,380,630	0
Preference shares						
At the beginning of the year	0	0	0	0	0	0
Increase during the year	0	0	0	0	0	0
i. Issues of shares	0	0	0	0	0	0
ii. Re-issue of forfeited shares	0	0	0	0	0	0
iii. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Redemption of shares	0	0	0	0	0	0

ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify						
At the end of the year	0	0	0	0	0	

ISIN of the equity shares of the company

(ii) Details of stock split/consolidation during the year (for each class of shares)

Class of shares		(i)	(ii)	(iii)
Before split / Consolidation	Number of shares			
	Face value per share			
After split / Consolidation	Number of shares			
	Face value per share			

(iii) Details of shares/Debentures Transfers since closure date of last financial year (or in the case of the first return at any time since the incorporation of the company) *

Nil

[Details being provided in a CD/Digital Media]

Yes No Not Applicable

Separate sheet attached for details of transfers

Yes No

Note: In case list of transfer exceeds 10, option for submission as a separate sheet attachment or submission in a CD/Digital Media may be shown.

Date of the previous annual general meeting	<input type="text" value="07/07/2021"/>
Date of registration of transfer (Date Month Year)	<input type="text"/>
Type of transfer	<input type="text"/> 1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock
Number of Shares/ Debentures/ Units Transferred	<input type="text"/> Amount per Share/ Debenture/Unit (in Rs.) <input type="text"/>

Ledger Folio of Transferor				<input type="text"/>			
Transferor's Name		<input type="text"/>		<input type="text"/>		<input type="text"/>	
		Surname		middle name		first name	
Ledger Folio of Transferee				<input type="text"/>			
Transferee's Name		<input type="text"/>		<input type="text"/>		<input type="text"/>	
		Surname		middle name		first name	

Date of registration of transfer (Date Month Year)				<input type="text"/>			
Type of transfer		<input type="text"/>		1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock			
Number of Shares/ Debentures/ Units Transferred		<input type="text"/>		Amount per Share/ Debenture/Unit (in Rs.)		<input type="text"/>	
Ledger Folio of Transferor				<input type="text"/>			
Transferor's Name		<input type="text"/>		<input type="text"/>		<input type="text"/>	
		Surname		middle name		first name	
Ledger Folio of Transferee				<input type="text"/>			
Transferee's Name		<input type="text"/>		<input type="text"/>		<input type="text"/>	
		Surname		middle name		first name	

(iv) * Debentures (Outstanding as at the end of financial year)

Particulars	Number of units	Nominal value per unit	Total value
Non-convertible debentures	2,000	1000000	2,000,000,000
Partly convertible debentures	0	0	0
Fully convertible debentures	0	0	0

Particulars	Number of units	Nominal value per unit	Total value
Total			2,000,000,000

Details of debentures

Class of debentures	Outstanding as at the beginning of the year	Increase during the year	Decrease during the year	Outstanding as at the end of the year
Non-convertible debentures	0	2,000,000,000	0	2,000,000,000
Partly convertible debentures	0	0	0	0
Fully convertible debentures	0	0	0	0

(v) Securities (other than shares and debentures)

0

Type of Securities	Number of Securities	Nominal Value of each Unit	Total Nominal Value	Paid up Value of each Unit	Total Paid up Value
Total					

V. *Turnover and net worth of the company (as defined in the Companies Act, 2013)

(i) Turnover

12,359,680,000

(ii) Net worth of the Company

10,429,900,000

VI. (a) *SHARE HOLDING PATTERN - Promoters

S. No.	Category	Equity		Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	12,030,406	17.66	0	
	(ii) Non-resident Indian (NRI)	0	0	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	

3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	33,900,000	49.75	0	
10.	Others	0	0	0	
	Total	45,930,406	67.41	0	0

Total number of shareholders (promoters)

3

(b) *SHARE HOLDING PATTERN - Public/Other than promoters

S. No.	Category	Equity		Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	0	0	0	
	(ii) Non-resident Indian (NRI)	51,835	0.08	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	

8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	21,356,370	31.34	0	
10.	Others GVK Bio Employees Welfare	799,452	1.17	0	
	Total	22,207,657	32.59	0	0

Total number of shareholders (other than promoters)

6

**Total number of shareholders (Promoters+Public/
Other than promoters)**

9

**VII. *NUMBER OF PROMOTERS, MEMBERS, DEBENTURE HOLDERS
(Details, Promoters, Members (other than promoters), Debenture holders)**

Details	At the beginning of the year	At the end of the year
Promoters	3	3
Members (other than promoters)	2	6
Debenture holders	0	5

VIII. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

(A) *Composition of Board of Directors

Category	Number of directors at the beginning of the year		Number of directors at the end of the year		Percentage of shares held by directors as at the end of year	
	Executive	Non-executive	Executive	Non-executive	Executive	Non-executive
A. Promoter	0	1	0	1	0	8.83
B. Non-Promoter	1	6	1	7	0	0
(i) Non-Independent	1	4	1	4	0	0
(ii) Independent	0	2	0	3	0	0
C. Nominee Directors representing	0	1	0	2	0	0
(i) Banks & FIs	0	0	0	0	0	0
(ii) Investing institutions	0	0	0	0	0	0
(iii) Government	0	0	0	0	0	0
(iv) Small share holders	0	0	0	0	0	0

(v) Others	0	1	0	2	0	0
Total	1	8	1	10	0	8.83

Number of Directors and Key managerial personnel (who is not director) as on the financial year end date 11

(B) (i) *Details of directors and Key managerial personnel as on the closure of financial year

Name	DIN/PAN	Designation	Number of equity share(s) held	Date of cessation (after closure of financial year : If any)
INDIRA KRISHNA RED	00005230	Director	0	01/06/2022
VENKATA SANJAYREDDY	00005282	Director	0	
DAVINDER SINGH BRAHMA	00068502	Director	6,015,203	
GERHARD MAYR	02734832	Director	0	
MANMAHESH KANTIPI	05241166	Director	0	
KESHAV GUNUPATI V	06593325	Director	0	
SAHAJBIR SINGH BRAHMA	07197320	Director	0	10/06/2022
ROBERT RICHARD RUSSELL	08404004	Director	0	
AJAY SRIVASTAVA	00049912	Director	0	
RAJAT SOOD	07914803	Director	0	
ADAM RICHARD DAWSON	09184061	Director	0	

(ii) Particulars of change in director(s) and Key managerial personnel during the year 7

Name	DIN/PAN	Designation at the beginning / during the financial year	Date of appointment/ change in designation/ cessation	Nature of change (Appointment/ Change in designation/ Cessation)
RAJAT SOOD	07914803	Additional director	19/05/2021	Appointment
AJAY SRIVASTAVA	00049912	Additional director	20/05/2021	Appointment
ADAM RICHARD DAWSON	09184061	Additional director	31/05/2021	Appointment
RAJAT SOOD	07914803	Director	19/05/2021	Change in Designation
AJAY SRIVASTAVA	00049912	Director	07/07/2021	Change in Designation
ADAM RICHARD DAWSON	09184061	Director	07/07/2021	Change in Designation
SANJIV DWARKANATH	01550413	Director	18/05/2021	Cessation

IX. MEETINGS OF MEMBERS/CLASS OF MEMBERS/BOARD/COMMITTEES OF THE BOARD OF DIRECTORS

A. MEMBERS/CLASS /REQUISITIONED/NCLT/COURT CONVENED MEETINGS

Number of meetings held

3

Type of meeting	Date of meeting	Total Number of Members entitled to attend meeting	Attendance	
			Number of members attended	% of total shareholding
Extra Ordinary General Mee	28/04/2021	5	4	84
Extra Ordinary General Mee	19/05/2021	8	6	82
Annual General Meeting	07/07/2021	8	8	100

B. BOARD MEETINGS

*Number of meetings held

5

S. No.	Date of meeting	Total Number of directors associated as on the date of meeting	Attendance	
			Number of directors attended	% of attendance
1	24/05/2021	10	10	100
2	26/07/2021	11	11	100
3	28/10/2021	11	11	100
4	28/01/2022	11	11	100
5	31/03/2022	11	11	100

C. COMMITTEE MEETINGS

Number of meetings held

7

S. No.	Type of meeting	Date of meeting	Total Number of Members as on the date of the meeting	Attendance	
				Number of members attended	% of attendance
1	AUDIT COMM	24/05/2021	3	3	100
2	AUDIT COMM	26/07/2021	3	3	100
3	AUDIT COMM	28/10/2021	3	3	100
4	AUDIT COMM	28/01/2022	3	3	100

S. No.	Type of meeting	Date of meeting	Total Number of Members as on the date of the meeting	Attendance	
				Number of members attended	% of attendance
5	NOMINATION	01/07/2021	4	4	100
6	NOMINATION	10/02/2022	4	4	100
7	CORPORATE	25/01/2022	4	4	100

D. *ATTENDANCE OF DIRECTORS

S. No.	Name of the director	Board Meetings			Committee Meetings			Whether attended AGM held on
		Number of Meetings which director was entitled to attend	Number of Meetings attended	% of attendance	Number of Meetings which director was entitled to attend	Number of Meetings attended	% of attendance	24/08/2022
								(Y/N/NA)
1	INDIRA KRISH	5	5	100	6	6	100	No
2	VENKATA SA	5	5	100	1	1	100	No
3	DAVINDER SI	5	5	100	3	3	100	No
4	GERHARD M	5	5	100	1	1	100	No
5	MANMAHESH	5	5	100	0	0	0	No
6	KESHAV GUN	5	5	100	0	0	0	Yes
7	SAHAJBIR SI	5	5	100	0	0	0	No
8	ROBERT RIC	5	5	100	2	2	100	No
9	AJAY SRIVAS	5	5	100	4	4	100	No
10	RAJAT SOOD	5	5	100	7	7	100	No
11	ADAM RICHA	4	4	100	0	0	0	No

X. *REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Nil

Number of Managing Director, Whole-time Directors and/or Manager whose remuneration details to be entered

1

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/Sweat equity	Others	Total Amount
1	MANMAHESH KAN	Director & CEO	54,835,707	0	382,720,728	252,222	437,808,657
	Total		54,835,707	0	382,720,728	252,222	437,808,657

Number of CEO, CFO and Company secretary whose remuneration details to be entered

0

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1							0
	Total						

Number of other directors whose remuneration details to be entered

8

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	DAVINDER SINGH	Director	0	0	0	302,222	302,222
2	VENKATA SANJAY	Director	0	0	0	252,222	252,222
3	INDIRA KRISHNA F	Director	0	0	0	403,333	403,333
4	KESHAV GUNUPA	Director	0	0	0	252,222	252,222
5	SAHAJBIR SINGH I	Director	0	0	0	259,070	259,070
6	GERHARD MAYR	Director	4,530,000	0	117,840,000	284,169	122,654,169
7	ROBERT RICHARD	Director	0	0	0	344,304	344,304
8	AJAY SRIVASTAVA	Director	0	0	0	353,333	353,333
	Total		4,530,000	0	117,840,000	2,450,875	124,820,875

XI. MATTERS RELATED TO CERTIFICATION OF COMPLIANCES AND DISCLOSURES

* A. Whether the company has made compliances and disclosures in respect of applicable provisions of the Companies Act, 2013 during the year Yes No

B. If No, give reasons/observations

XII. PENALTY AND PUNISHMENT - DETAILS THEREOF

(A) DETAILS OF PENALTIES / PUNISHMENT IMPOSED ON COMPANY/DIRECTORS /OFFICERS Nil

Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which penalised / punished	Details of penalty/ punishment	Details of appeal (if any) including present status

(B) DETAILS OF COMPOUNDING OF OFFENCES Nil

1

Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which offence committed	Particulars of offence	Amount of compounding (in Rupees)
ARAGEN LIFE SC	RESERVE BANK C	02/03/2022	Foreign Exchange M	Delayed reporting c	36,250

XIII. Whether complete list of shareholders, debenture holders has been enclosed as an attachment

Yes No

XIV. COMPLIANCE OF SUB-SECTION (2) OF SECTION 92, IN CASE OF LISTED COMPANIES

In case of a listed company or a company having paid up share capital of Ten Crore rupees or more or turnover of Fifty Crore rupees or more, details of company secretary in whole time practice certifying the annual return in Form MGT-8.

Name

A.BHIMESWARA RAO

Whether associate or fellow

Associate Fellow

Certificate of practice number

13380

I/We certify that:

- (a) The return states the facts, as they stood on the date of the closure of the financial year aforesaid correctly and adequately.
 (b) Unless otherwise expressly stated to the contrary elsewhere in this Return, the Company has complied with all the provisions of the Act during the financial year.
 (c) The company has not, since the date of the closure of the last financial year with reference to which the last return was submitted or in the case of a first return since the date of the incorporation of the company, issued any invitation to the public to subscribe for any securities of the company.
 (d) Where the annual return discloses the fact that the number of members, (except in case of a one person company), of the company exceeds two hundred, the excess consists wholly of persons who under second proviso to clause (ii) of sub-section (68) of section 2 of the Act are not to be included in reckoning the number of two hundred.

Declaration

I am Authorised by the Board of Directors of the company vide resolution no. ... dated

(DD/MM/YYYY) to sign this form and declare that all the requirements of the Companies Act, 2013 and the rules made thereunder in respect of the subject matter of this form and matters incidental thereto have been complied with. I further declare that:

- Whatever is stated in this form and in the attachments thereto is true, correct and complete and no information material to the subject matter of this form has been suppressed or concealed and is as per the original records maintained by the company.
- All the required attachments have been completely and legibly attached to this form.

Note: Attention is also drawn to the provisions of Section 447, section 448 and 449 of the Companies Act, 2013 which provide for punishment for fraud, punishment for false statement and punishment for false evidence respectively.

To be digitally signed by

Director

MANMAHESH
SH
KANTIPUDI
Digitally signed by
MANMAHESH
KANTIPUDI
Date: 2022.10.22
12:20:55 +05'30'

DIN of the director

05241166

To be digitally signed by

KASTURI
RAMAKRISHNA
HNA
Digitally signed by
KASTURI
RAMAKRISHNA
Date: 2022.10.22
12:21:46 +05'30'

Company Secretary

Company secretary in practice

Membership number

Certificate of practice number

Attachments

1. List of share holders, debenture holders
2. Approval letter for extension of AGM;
3. Copy of MGT-8;
4. Optional Attachment(s), if any

Attach
Attach
Attach
Attach

List of attachments

List of share and Debenture holders as on MGT-8_Aragen Life Sciences-2021-22.pdf
List of shares and Debentures transfers-Ar
List of shareholders-Scheme-Aragen Life S
explanation letter-Aragen Life Sciences MC

Remove attachment

Modify

Check Form

Prescrutiny

Submit

This eForm has been taken on file maintained by the Registrar of Companies through electronic mode and on the basis of statement of correctness given by the company




ARAGEN LIFE SCIENCES PRIVATE LIMITED

List of Shareholders of the Company as on 31.03.2022

S. No.	DP ID	Client ID	Name of the Shareholders	No. of Shares	%
1.	IN302084	10009740	GVK Davix Technologies Private Limited	33,900,000	49.75
2.	IN305099	10008438	D S Brar	6,015,203	8.83
3.	IN302084	10010673	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	6,015,203	8.83
4.	--	63	GVK Bio Employees Welfare Trust	799,452	1.17
5.	IN301524	30053402	Goldman Sachs Capital Holdings III Pte. Ltd.	5,159,708	7.57
6.	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. Ltd.	4,699,518	6.90
7.	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11,141,008	16.35
8.	IN301524	30053363	WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.	356,136	0.52
9.	--	67	Tarun Khanna	51,835	0.08
Total No. of Shares				68,138,063	100.00

For Aragen Life Sciences Private Limited


Ramakrishna Kasturi
Company Secretary




ARAGEN LIFE SCIENCES PRIVATE LIMITED

List of Debentureholders of the Company as on 31.03.2022

S.No.	DP ID	Client ID	Name of the Debentureholder	No.of Debentures	%
1.	IN303270	10037180	Yes Bank Limited	1250	62.5
2.	IN302927	10368383	Madhya Bharat Phosphate Private Limited	39	1.95
3.	IN302927	10365688	Kisan Phosphates Private Limited	183	9.15
4.	IN302927	10348931	Shree Pushkar Chemicals And Fertilisers Limited	128	6.4
5.	IN301330	21716964	Tata Capital Financial Services Ltd	400	20
Total No. of Debentures				2000	100.00

For Aragen Life Sciences Private Limited


Ramakrishna Kasturi
Company Secretary

**FORM NO. MGT-8**


Pursuant to Section 92 (2) of the Companies Act, 2013 and Rule 11 (2) of Companies
(Management and Administration) Rules, 2014

CERTIFICATE BY A COMPANY SECRETARY IN PRACTICE

I have examined the registers, records and books and papers of **M/s. ARAGEN LIFE SCIENCES PRIVATE LIMITED** (formerly known as **GVK BIOSCIENCES PRIVATE LIMITED**) having its registered office at Plot 28A, IDA Nacharam, Hyderabad-500076. TG. (hereafter referred to as the Company) as required to be maintained under the Companies Act, 2013 ('the Act') and the rules made there under for the Financial Year ended on 31st March, 2022. In my opinion and to the best of my information and according to the examinations carried out by me and explanations furnished to me by the company, its officers and agents, and I certify that:

- A. The Annual Return states the facts as at the close of the aforesaid Financial Year correctly and adequately.
- B. During the aforesaid Financial Year the Company has complied with provisions of the Act & Rules made there under in respect of:

S. No	Particulars	Remarks
1	Its status under the Act;	Complied with the provisions of the Act, as a Private Limited Company.
2	Maintenance of registers/ records & making entries there in within the time prescribed there for;	As confirmed to me, the entries in the registers were made within the prescribed time.
3	Filing of forms and returns as stated in the Annual Return, with the Registrar of Companies, Regional Director, Central Government, the Tribunal, Court or other authorities within/ beyond the prescribed time;	The Forms and Returns were filed with the Registrar of Companies are within the prescribed time/some forms beyond the prescribed time with necessary additional fee.
4	Calling/ convening/ holding meetings of Board of Directors or its committees, if any, and the meetings of the members of the company on due dates as stated in the annual return in respect of which meetings, proper notices	The meetings of Board of Directors and its Committees were held on the due dates as mentioned in the Annual Return in respect of which meetings proper notices were given and the proceedings were properly recorded and signed the Minutes Book maintained for the purpose/registers maintained for the





	were given and the proceedings including the circular resolutions have been properly recorded in the Minute Book/registers maintained for the purpose and the same have been signed;	purpose and the same have been signed. The Meetings of the Members of the Company were duly held on due dates as stated in the annual return in respect of which meetings, proper notices were given and the proceedings have been properly recorded in the Minutes Book/registers maintained for the purpose and the same have been signed.
5	Closure of Register of Members/ Security holders, as the case may be.	The Company has not closed the Register of Member/Security holders.
6	Advances/loans to its directors and/or persons or firms or companies referred in section 185 of the Act;	During the year, the Company has not provided any loans/advances to its directors and/or persons or firms or companies referred in section 185 of the Act;
7	Contracts/arrangements with related parties as specified in section 188 of the Act;	The Company Complied with the provisions of Section 188(1) of the Companies Act, 2013.
8	Issue or allotment or transfer or transmission or buy back of securities/ redemption of preference shares or debentures/ alteration or reduction of share capital/ conversion of shares/ securities and issue of security certificates in all instances;	There was no transmission or buy-back of securities/redemption of preference shares /debentures during the year. The Company has also not carried out any reduction of share capital/conversion of shares/securities during the year. During the year, the Company has allotted equity shares to employees through the stock option schemes and there were transfers of shares. The Company issued 2000 (Two Thousand) listed, rated, secured, redeemable, nonconvertible debentures of the face value of Rs. 10,00,000/- (INR Ten Lakhs) each, aggregating up to Rs 200 Crores (INR Two Hundred Crores) (NCDs/Securities) in dematerialized form through Private Placement, and listed on stock exchange – BSE Limited.
9	Keeping in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares in compliance with the provisions of the Act	There were no transactions necessitating the Company to keep in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares.



10	Declaration/ payment of dividend; transfer of unpaid/ unclaimed dividend/other amounts as applicable to the Investor Education and Protection Fund in accordance with section 125 of the Act;	<p>No Dividend was declared and paid during the FY 2021-22. However, a final dividend of Rs. 8.64/- per equity share has been declared and paid for the Financial Year 2021-22 in FY23.</p> <p>The Company was not required to transfer any amount to the Investor Education and Protection Fund as there is no unpaid/ unclaimed dividend, matured deposits, matured debentures and the interest accrued thereon, in accordance with Section 125 of the Act.</p>
11	Signing of audited financial statement as per the provisions of section 134 of the Act and report of directors is as per sub – sections (3), (4) and (5) thereof;	The Company has complied with the provisions of the Section 134 of the Act.
12	Constitution/ appointment/ re-appointments/ retirement/ filling up casual vacancies/ disclosures of the Directors, Key Managerial Personnel and the remuneration paid to them;	<p>During the year, one (1) Director resigned from the Company and three (3) were appointed as Additional Directors, who were subsequently regularized as Directors of the Company at the General Meetings held during the year. Due compliance is made in respect of the Constitution/disclosures/ appointment of the Directors.</p> <p>Being a Private Limited Company, provisions related to Key Managerial Personnel are not applicable to the Company.</p> <p>Directors were paid remuneration as Provided in the Form MGT-7.</p>
13	Appointment/ reappointment/ filling up casual vacancies of auditors as per the provisions of section 139 of the Act;	The Company has complied with the provisions of Section 139 of the Act, with respect to Appointment of Statutory Auditors of the Company.
14	Approvals required to be taken from the Central Government, Tribunal, Regional Director, Registrar, Court or such other authorities under the various provisions of the Act;	During the financial year the Company was not required to obtain any approvals from the Central Government, Tribunal, Regional Director, Registrar, Court or such other authorities under the various provisions of the Act except below:





		<p>During the previous year, Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited (GVK Davix), GVK Davix Research Private Limited and the Company and their respective shareholders have entered a Composite Scheme of Arrangement under Section 230 to 232 of the Companies Act, 2013 ("Scheme") which contemplates amalgamation of the residual GVK Davix post demerger of its informatics business excluding the investment in the Company, into the Company.</p> <p>During the year, All companies involved in the Scheme have filed Joint Petition with NCLT for approval to the Scheme.</p> <p>Post the year under review, the said Scheme was approved by the National Company Law Tribunal, Hyderabad Bench ("NCLT") on 30th May 2022 and the Company has received the final order copy on 07th June 2022. The certified copy of the said order has been filed with the Registrar of Companies, Hyderabad by the companies involved. The Company filed the certified copy of the Order on 01st July 2022 with respect to Part IV of the Scheme concerning the amalgamation of GVK Davix with the Company, and the amalgamation has become operative from that date.</p>
15	Acceptance/renewal/repayment of deposits;	<p>During the year, the Company did not accept any deposits covered under the Chapter V of the Companies Act, 2013. However, pursuant to the Composite Scheme of Arrangement, the Unsecured loans of GVK Davix Technologies Private Limited (transferee Company) availed deposits from its shareholders amounting to Rs. 49.82 million have been transferred to the Company and the Company has repaid entire loan/deposit amount post the year under review.</p>
16	Borrowings from its directors, members, public financial institutions, banks and others and	<p>The Company has made borrowings from the Banks/financial institutions and complied with the provisions with the Act.</p>





ABR & ASSOCIATES

Company Secretaries

B-41/A, Sai Sikhara, Ground Floor,
Madhura Nagar, Hyderabad-38.

Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

	creation/ modification/ satisfaction of charges in that respect, wherever applicable;	<p>In relation to Non-Convertible Debentures issued and allotted during the year, the Company created a charge in favour of Debenture trustee and filed necessary forms with Registrar of Companies.</p> <p>The Company has not made any borrowings from its directors, members, public financial institutions and others.</p>
17	Loans and investments or guarantees given or providing of securities to other bodies corporate or persons falling under the provisions of section 186 of the Act;	<p>The Company has not given any loans, guarantees or provided securities or acquired securities of any other body corporate exceeding the limits specified in Section 186(2) of the Companies Act.</p> <p>During the year, the Company acquired 56.82% shares of 'Intox Private Limited' in December 2021 with approval of board of directors of the Company.</p> <p>'Aragen Foundation' a Section-8 Company with charitable objects was incorporated as a wholly-owned subsidiary of the Company during the year.</p>
18	Alteration of the provisions of the Memorandum and/ or Articles of Association of the Company;	<p>During the year under review.</p> <p>The Company has altered the provisions of Articles of Association during the year and no alterations made to Memorandum of Association.</p>

For ABR & ASSOCIATES
Company Secretaries



A. Bhimeswara Rao

(A. BHIMESWARA RAO)

Proprietor

M. No. 35521; C.P No.13380.

ICSI UDIN: A035521D001044716

Place: Hyderabad

Date: 26.09.2022




ARAGEN LIFE SCIENCES PRIVATE LIMITED

Equity Share Transfers during 01.04.2021 to 31.03.2022

S. No	DP & Client ID/Folio No. of Transferor	Name of the Transferor	DP & Client ID of Transferee	Name of the Transferee	No. of shares transferred	Consideration per equity share	Date of transfer (Date of Board of Directors approval)
1.	17	Ramesh Gambhir	63	GVK Bio Employees Welfare Trust	17566	INR 877.46	18/05/2021
2.	64	Manmahesh Kantipudi	63	GVK Bio Employees Welfare Trust	506800	INR 877.46	18/05/2021
3.	72	Sudhir Kumar Singh	63	GVK Bio Employees Welfare Trust	107037	INR 877.46	18/05/2021
4.	73	Suresh Anubolu	63	GVK Bio Employees Welfare Trust	47718	INR 877.46	18/05/2021
5.	74	Krishna S Ethiraj	63	GVK Bio Employees Welfare Trust	23410	INR 877.46	18/05/2021
6.	75	Somesh Sharma	63	GVK Bio Employees Welfare Trust	33460	INR 877.46	18/05/2021
7.	76	Amit Kumar Rustagi	63	GVK Bio Employees Welfare Trust	21535	INR 877.46	18/05/2021
8.	77	Sreehari Babu Putchakayala	63	GVK Bio Employees Welfare Trust	19106	INR 877.46	18/05/2021
9.	78	KMV Narayana Rao	63	GVK Bio Employees Welfare Trust	12743	INR 877.46	18/05/2021


Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
(Formerly known as GVK Biosciences Pvt. Ltd.)
28 A, IDA Nacharam, Hyderabad 500 076, India
T: +91 40 6692 9999 F: +91 40 6692 9900
W: aragen.com CIN: U74999TG2000PTC035826





10.	79	Muralidharan Kaliyaperumal	63	GVK Bio Employees Welfare Trust	11430	INR 877.46	18/05/2021
11.	80	Ramakrishna Kasturi	63	GVK Bio Employees Welfare Trust	14397	INR 877.46	18/05/2021
12.	81	Rongali Bangaru Babu	63	GVK Bio Employees Welfare Trust	8712	INR 877.46	18/05/2021
13.	82	Timmanna Upadhya	63	GVK Bio Employees Welfare Trust	10554	INR 877.46	18/05/2021
14.	83	Lakshman E Rajagopalan	63	GVK Bio Employees Welfare Trust	24564	INR 877.46	18/05/2021
15.	IN300126 11259035	Destiny Investments Limited	85 (IN301524 30053146)	Goldman Sachs Asia Strategic Pte. Ltd.	2,714,419	INR 877.46	19/05/2021
16.	IN300126 11259035	Destiny Investments Limited	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	2,472,323	INR 877.46	19/05/2021
17.	IN300126 11259035	Destiny Investments Limited	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	5,861,062	INR 877.46	19/05/2021
18.	IN300126 11259035	Destiny Investments Limited	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	187,356	INR 877.46	19/05/2021
19.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	1,088,945	INR 877.46	19/05/2021


Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
 (Formerly known as GVK Biosciences Pvt. Ltd.)
 28 A, IDA Nacharam, Hyderabad 500 076, India
 T: +91 40 6692 9999 F: +91 40 6692 9900
 W: aragen.com CIN: U74999TG2000PTC035826





20.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	991,823	INR 877.46	19/05/2021
21.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	2,351,286	INR 877.46	19/05/2021
22.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	75,163	INR 877.46	19/05/2021
23.	(IN305099 10008438)	Davinder Singh Brar	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	1,088,946	INR 877.46	19/05/2021
24.	(IN305099 10008438)	Davinder Singh Brar	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	991,824	INR 877.46	19/05/2021
25.	(IN305099 10008438)	Davinder Singh Brar	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	2,351,287	INR 877.46	19/05/2021
26.	(IN305099 10008438)	Davinder Singh Brar	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	75,160	INR 877.46	19/05/2021
27.	63	GVK BIO Employees' Welfare Trust	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	2,08,267	INR 877.46	19/05/2021
28.	63	GVK BIO Employees' Welfare Trust	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	1,89,692	INR 877.46	19/05/2021


Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
 (Formerly known as GVK Biosciences Pvt. Ltd.)
 28 A, IDA Nacharam, Hyderabad 500 076, India
 T: +91 40 6692 9999 F: +91 40 6692 9900
 W: aragen.com CIN: U74999TG2000PTC035826





29.	63	GVK BIO Employees' Welfare Trust	86 (IN30152430053138)	WSCPVIII (Singapore) Pte. Ltd.	4,49,697	INR 877.46	19/05/2021
30.	63	GVK BIO Employees' Welfare Trust	87 (IN30152430053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	14376	INR 877.46	19/05/2021
31.	67	Tarun Khanna	84 (IN30152430044045)	Goldman Sachs Asia Strategic Pte. Ltd.	18785	INR 877.46	12/08/2021
32.	67	Tarun Khanna	85 (IN30152430053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	17110	INR 877.46	12/08/2021
33.	67	Tarun Khanna	86 (IN30152430053138)	WSCPVIII (Singapore) Pte. Ltd.	40562	INR 877.46	12/08/2021
34.	67	Tarun Khanna	87 (IN30152430053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	1296	INR 877.46	12/08/2021
35.	88	Gerhard Mayr	84 (IN30152430044045)	Goldman Sachs Asia Strategic Pte. Ltd.	33824	INR 877.46	12/08/2021
36.	88	Gerhard Mayr	85 (IN30152430053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	30807	INR 877.46	12/08/2021
37.	88	Gerhard Mayr	86 (IN30152430053138)	WSCPVIII (Singapore) Pte. Ltd.	73034	INR 877.46	12/08/2021
38.	88	Gerhard Mayr	87 (IN30152430053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	2335	INR 877.46	12/08/2021


Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
 (Formerly known as GVK Biosciences Pvt. Ltd.)
 28 A, IDA Nacharam, Hyderabad 500 076, India
 T: +91 40 6692 9999 F: +91 40 6692 9900
 W: aragen.com CIN: U74999TG2000PTC035826





39.	89	Srinivas Reddy Mamidi	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	3775	INR 877.46	27/08/2021
40.	89	Srinivas Reddy Mamidi	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	3438	INR 877.46	27/08/2021
41.	89	Srinivas Reddy Mamidi	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	8151	INR 877.46	27/08/2021
42.	89	Srinivas Reddy Mamidi	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	261	INR 877.46	27/08/2021
43.	90	Brian Michael Shaughnessy	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	2,747	INR 877.46	06/10/2021
44.	90	Brian Michael Shaughnessy	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	2,501	INR 877.46	06/10/2021
45.	90	Brian Michael Shaughnessy	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	5,929	INR 877.46	06/10/2021
46.	90	Brian Michael Shaughnessy	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	189	INR 877.46	06/10/2021
47.	(IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	(IN301524 30053402)	Goldman Sachs Capital Holdings III Pte. Ltd	5159708	INR 877.46	08/11/2021

Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
(Formerly known as GVK Biosciences Pvt. Ltd.)
28 A, IDA Nacharam, Hyderabad 500 076, India
T: +91 40 6692 9999 F: +91 40 6692 9900
W: aragen.com CIN: U74999TG2000PTC035826





48.	(IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	(IN301524 30053363)	WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.	356136	INR 877.46	08/11/2021
-----	------------------------	--	------------------------	--	--------	------------	------------

For Aragen Life Sciences Private Limited

Ramakrishna Kasturi
Company Secretary




ARAGEN LIFE SCIENCES PRIVATE LIMITED

Debenture Transfers (through demat mode) during FY 2022

S. No	DP & Client ID/Folio No. of Transferor	Name of the Transferor	DP & Client ID of Transferee	Name of the Transferee	No. of Debentures transferred	Period of Transfer
1	IN302927 10338169	JM Financial Products Ltd	IN301330 21716964	Tata Capital Financial Services Ltd	400	Between 04.03.2022 to 11.03.2022
2	IN302927 10338169	JM Financial Products Ltd	IN302927 10348931	Shree Pushkar Chemicals and Fertilisers Limited	65	Between 04.03.2022 to 11.03.2022
3	IN302927 10338169	JM Financial Products Ltd	IN302927 10365688	Kisan Phosphates Private Limited	183	Between 04.03.2022 to 11.03.2022
4	IN302927 10338169	JM Financial Products Ltd	IN302927 10368383	Madhya Bharat Phosphate Private Limited	102	Between 04.03.2022 to 11.03.2022
5	IN302927 10368383	Madhya Bharat Phosphate Private Limited	IN302927 10348931	Shree Pushkar Chemicals and Fertilisers Limited	63	Between 25.03.2022 to 31.03.2022

For Aragen Life Sciences Private Limited


Ramakrishna Kasturi
Company Secretary




ARAGEN LIFE SCIENCES PRIVATE LIMITED

List of Shareholders of the Company as on 31.03.2022

(Prior to the Composite Scheme of Arrangement)

S. No.	DP ID	Client ID	Name of the Shareholders	No. of Shares	%
1.	IN302084	10009740	GVK Davix Technologies Private Limited*	33,900,000	49.75
2.	IN305099	10008438	D S Brar	6,015,203	8.83
3.	IN302084	10010673	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	6,015,203	8.83
4.	--	63	GVK Bio Employees Welfare Trust	799,452	1.17
5.	IN301524	30053402	Goldman Sachs Capital Holdings III Pte. Ltd.	5,159,708	7.57
6.	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. Ltd.	4,699,518	6.90
7.	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11,141,008	16.35
8.	IN301524	30053363	WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.	356,136	0.52
9.	--	67	Tarun Khanna	51,835	0.08
Total No. of Shares				68,138,063	100.00

* Pursuant to the composite scheme of arrangement between Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited ("GVK Davix Tech"), GVK Davix Research Private Limited and our Company, approved by the National Company Law Tribunal, Hyderabad Bench pursuant to an order dated May 30, 2022 and Effective from 1st July 2022 (i.e. date of filing of NCLT order with ROC) ("**Composite Scheme of Arrangement**"), amongst other things, 33,900,000 Equity Shares that were previously held by GVK Davix Tech in the Company were automatically cancelled upon 33,900,000 Equity Shares being issued and allotted by our Company to the shareholders of GVK Davix Tech on 7th July 2022, in proportion to the number of Equity Shares held by them in GVK Davix Tech. Further, pursuant to the Composite Scheme of Arrangement, GVK Davix Tech amalgamated with the Company and ceased to be a shareholder of the Company and no longer exists as on the date.


For Aragen Life Sciences Private Limited

Ramakrishna Kasturi
Company Secretary



List of Shareholders of the Company as on 21st October 2022
(Post effectuation of the Composite Scheme of Arrangement)

S. No.	DP ID	Client ID	Name of the Shareholders	No. of shares	%
1	IN305099	10008438	D S Brar#	16554971	24.30
2	IN302084	10010673	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	22056824	32.37
3	--	63	GVK Bio Employees Welfare Trust	799452	1.17
4	IN301524	30053402	Goldman Sachs Capital Holdings III Pte. Ltd.	5159708	7.57
5	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. Ltd.	4699518	6.90
6	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11141008	16.35
7	IN301524	30053363	WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.	356136	0.52
8	--	67	Tarun Khanna	51835	0.08
9	IN301774	10005267	Madhubani Investments Private Limited	6410232	9.41
10	--	95	Aparna Reddy Gunupati (as a Trustee of Reddy Family Trust)	908379	1.33
Total				68138063	100.00

#Including transfer of 161111 equity shares from Mr. Anandbir Singh Brar on 17th August 2022.

For Aragen Life Sciences Private Limited

Ramakrishna Kasturi
Company Secretary



TO WHOM SO EVER IT MAY CONCERN

Sub: Form MGT-7 Annual Return for FY22 of the Company.

This is to inform that, during the year, the Company allotted 1155611 equity shares under ESOP schemes of the Company and subsequently out of total allotted shares 1103776 shares were transferred (i.e. except 51835 shares) to other shareholders of the Company and these transferred shares got dematerialized during the year.

With respect to the Breakup of paid-up share capital section of form MGT-7: Out of opening balance of physical shares i.e., 802452 equity shares, 3000 shares were transferred to other shareholders and these transferred shares got dematerialized during the year and there is no specific column to show the details of shares which were dematerialized during the year in the form and we tried to show these 3000 dematerialized shares in others column of increased and decreased share capital line items but due to technical issue these details were not captured in the respective columns. So, in order to match with the closing balance of physical and demat shares, we have shown in physical mode 48835 shares instead of 51835 shares by reducing 3000 transferred shares and in demat mode 1106776 instead of 1103776 with addition of 3000 transferred shares in increase of paid-up share capital column under the ESOP item.

Please consider the above and take on record.

Thanking you,

For Aragen Life Sciences Private Limited

KASTURI
RAMAKRISHN
A

Digitally signed by
KASTURI RAMAKRISHNA
Date: 2022.10.22
12:12:53 +05'30'

Ramakrishna Kasturi
Company Secretary
Date:22-10-2022

Registered & Corporate Office

Aragen Life Sciences Pvt. Ltd.

(Formerly known as GVK Biosciences Pvt. Ltd.)
28A, IDA Nacharam, Hyderabad – 500 076, India.
T +91 40 6692 9999 F +91 40 6692 9900
www.aragen.com CIN: U74999TG2000PTC035826